FDA Approves First New Alzheimer’s Drug in Nearly Two Decades

Marwan Sabbagh, MD, shares details about a new Alzheimer's drug that received FDA approval.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

Additional Assets

*Email us for video download password Content is property of Cleveland Clinic and for news media use only.

Media Contact

We're available to shoot custom interviews & b-roll for media outlets upon request.

There’s good news for people in the early stages of Alzheimer’s disease.

For the first time in nearly two decades, the Food and Drug Administration (FDA) has approved a drug to slow progression of the disease.

“Aducanumab is what’s called a monoclonal antibody, it’s an IV-infused manufactured protein that actually is supposed to find the amyloid in the brain and the body and grab it and remove it,” said Marwan Sabbagh, MD, Director of Translational Research at Cleveland Clinic Lou Ruvo Center for Brain Health, who took part in the drug trials.

Amyloid is a protein that forms in the brain and over time creates plaques which are believed to damage brain structures, leading to what we know as dementia.

This new drug targets amyloid and removes it during the very beginning stages of Alzheimer’s to slow damage to the brain.

It doesn’t reverse damage that’s already been done or improve symptoms, but it may give people more time before advanced dementia sets in.

“We in the field have been waiting, not just physicians and scientists, but patients and caregivers have been waiting for some really impactful treatment,” said Dr. Sabbagh. “I want to over emphasize that this drug does not make people better but it does slow the decline.”

*EDITOR’S NOTE: Dr. Sabbagh is a paid scientific advisor for Biogen.

For Journalists Only

Sign up below to be added to our Daily Health Stories distribution list.

For more information on medical conditions and diseases, visit our Health Library.